Anlotinib at 1.25, 2.5, or 5.0 μmol/L suppressed the mRNA expression of ABCB1 or ABCG2 in HT-29, LoVo, HCT116, or HCT116/L CRC cells (Fig. 4A). The gene discussed is ABCG2; the disease is colorectal carcinoma.